ClinicalTrials.gg
WithdrawnNCT06390722Sleep UpUpdated Sep 19, 2024

A Study to Assess the Effect of Upadacitinib in Atopic Dermatitis-induced Sleep Disturbance in Adults With Moderate to Severe Atopic Dermatitis

A Phase 3 interventional study of Upadacitinib and Placebo for Upadacitinib in Atopic Dermatitis and Sleep Disturbance, sponsored by AbbVie. Withdrawn. Open to participants aged 25 Years to 63 Years. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Why this study was withdrawn
strategic decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
25 Years to 63 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing upadacitinib in Dermatitis, Atopic — 2 open to participants now, 6 under way, 4 of them phase 3. upadacitinib · Dermatitis, Atopic.

Enrollment
16th of 17
0 · median 272
Started
2024
with 3 others
Phase 3
12 of 17
none open now
Registered
13th of 17
by date
Lead sponsor
15 of 17
AbbVie

Among the 17 studies testing upadacitinib in Dermatitis, Atopic, this one is the 16th largest by enrollment, is one of 4 that started in 2024, is one of 12 in phase 3, and was the 13th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

2 of the 17 studies testing upadacitinib in Dermatitis, Atopic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About upadacitinib

upadacitinib: first FDA approval 2019 (RINVOQ), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 25 Years to 63 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing upadacitinib in Dermatitis, Atopic, or all of them as a file.
02

Study summary

Many people with atopic dermatitis (AD) experience sleep disturbances. Greater sleep disturbances are associated with greater burden including increased sick days and impaired cognition. Patient focused research has found that sleep was one of the 3 most problematic symptoms for people with AD and their families.

Upadacitinib demonstrated clinically meaningful sleep improvement based on patient-reported outcome measures such as the Atopic Dermatitis Impact Scale (ADerm-IS) Sleep Domain score in Phase 3 registrational trials, but objective data on upadacitinib's effect on elements of sleep disturbance such as Wake After Sleep Onset, or Sleep Efficiency, have not been collected.

Upadacitinib is an approved drug for the treatment of moderate to severe atopic dermatitis (AD). This study is conducted in 2 Periods. During Period 1, participants are randomly assigned into 1 of 2 groups called treatment arms to receive upadacitinib or Placebo. In Period 2, participants will be switched to receive open-label upadacitnib. Approximately 112 adult participants ages 25 to 63 with moderate to severe AD who have moderate to severe sleep disturbance will be enrolled at up to 32 sites worldwide.

This study consists of a 35-day Screening Period; a 2-week randomized, double-blinded period (Period 1); a 22-week open-label extension period (Period 2); and a 30-day follow-up visit/call. Participants will receive oral tablets once per day of Upadacitinib or Placebo for 2 weeks followed by Upadacitinib oral tablet for 22 weeks

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

03

Conditions studied

  • Atopic Dermatitis
  • Sleep Disturbance

Browse trials for

Keywords

  • Upadacitinib
  • RINVOQ
  • ABT-494
  • Atopic Dermatitis
  • Sleep Disturbance
04

Who can participate

Ages eligible
25 Years to 63 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • AD, according to Hanifin and Rajka criteria, with onset of symptoms at least 3 years prior to Baseline.
  • Eczema Area and Severity Index (EASI) score >= 16; validated Investigator Global Assessment scale for Atopic Dermatitis (vIGA-AD) score >= 3, and >= 10% Body Surface Area (BSA) of AD involvement at the Baseline Visit.
  • Baseline weekly average of daily Worst Pruritus Numeric Rating Scale (NRS) >= 7.
  • Moderate to severe sleep disturbance as confirmed by Baseline Patient Global Impression (PGI) Sleep AD (7-day) score of 3 or 4.
  • Documented history of inadequate response to at least 1 prior systemic treatment for AD OR for whom systemic treatments, other than upadacitinib, are medically inadvisable (e.g., because of important side effects or safety risks).

Exclusion criteria

Exclusion Criteria:

  • Prior exposure to dupilumab, tralokinumab, lebrikizumab, or nemolizumab.
  • Conditions or circumstances that could interfere with sleep assessments, including but not limited to:

    • History of sleep apnea, hypersomnia, or insomnia related to chronic pain;
    • Participant uses a continuous positive airway pressure (CPAP) machine;
    • History of or uncontrolled asthma;
    • Evidence of restless leg syndrome;
    • Participant is an evening or night shift worker;
    • Participant has sleep disturbance due to menopause, nocturia, or situational circumstances (e.g., caring for infant).
  • Participants who had prior exposure to any oral JAK inhibitor
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Upadacitinib

    Participants randomized to receive upadacitinib Dose A once daily for 2 weeks during double-blind treatment period. At week 2, participants will be switched to open-label upadacitinib Dose A once daily for 22 weeks.

    Drug: Upadacitinib

  • Placebo comparator
    Placebo

    Participants randomized to receive Placebo once daily for 2 weeks during double-blind treatment period. At week 2, participants will be switched to open-label upadacitinib Dose A once daily for 22 weeks.

    Drug: Placebo for Upadacitinib

Interventions

  • Oral Tablet

    Also known as: RINVOQ

  • DrugPlacebo for Upadacitinib

    Oral Tablet

06

What researchers measure

Primary outcomes

  1. Percentage of participants achieving an improvement (reduction) in Worst Pruritus Numeric Rating Scale ≥ 4 from Baseline

    The Worst Pruritus Numeric Rating Scale is an assessment tool that participants used to report the intensity of their pruritus during a daily recall period. On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst imaginable itch'.

    Time frame: Baseline to Week 2

Secondary outcomes

  1. Change from Baseline in Total Scratch Time

    Scratch time will be measured in duration of seconds based on a wearable scratch sensor per sleep opportunity hour at Week 2 . Note: Sleep opportunity is defined as total time spent trying to sleep \[i.e., sleep sensor on to sensor off time\].

    Time frame: Baseline to Week 2

  2. Change from Baseline in Sleep Efficiency

    A wearable sleep sensor collects actigraphy, temperature, and heart rate data to quantify sleep parameters

    Time frame: Baseline to Week 2

  3. Change from Baseline in Wake After Sleep Onset (WASO) based on a sleep sensor.

    A wearable sleep sensor collects actigraphy, temperature, and heart rate data to quantify sleep parameters

    Time frame: Baseline to Week 2

  4. Change from Baseline in Nocturnal Scratching Bouts (≥ 5 seconds)

    Scratch time will be measured in duration of seconds based on a wearable scratch sensor per sleep opportunity hour at Week 2 . Note: Sleep opportunity is defined as total time spent trying to sleep \[i.e., sleep sensor on to sensor off time\].

    Time frame: Baseline to Week 2

07

Study locations

No study locations are listed for this record.

08

References and documents

Related links

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2024; primary completion for Jan 2026, 19 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2024
First posted
Apr 30, 2024
StartEst.
May 23, 2024
Primary completionEst.
Jan 5, 2026
CompletionEst.
Jul 8, 2026
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06390722
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Apr 30, 2024
Start date
May 23, 2024 (estimated)
Primary completion
Jan 5, 2026 (estimated)
Completion
Jul 8, 2026 (estimated)
Last update
Sep 19, 2024

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Upadacitinib

Start the discussion